Hemophilia Therapeutics Market, Global Outlook and Forecast 2023-2029

Report ID: MMG251330 | Category: Medical Care | Pages: 62 | Format: PDF | Published Date: October 26,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marrow, to help the blood clot. Hemophilia is passed from parents to children through genes.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Therapeutics. This report contains market size and forecasts of Hemophilia Therapeutics in global, including the following market information:
Global Hemophilia Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hemophilia Therapeutics market was valued at US$ 9756 million in 2022 and is projected to reach US$ 13580 million by 2029, at a CAGR of 4.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Hemophilia A Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hemophilia Therapeutics include Bayer AG, Pfizer, Inc., Novo Nordisk A/S, Baxter International Inc., Biogen Idec, Inc., Genetics Institute, Alpha Therapeutics Corporation, Expression Therapeutics and Swedish Orphan Biovitrum AB., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemophilia Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia Therapeutics Market Segment Percentages, by Type, 2022 (%)
Hemophilia A
Hemophilia B
Hemophilia C
Global Hemophilia Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Global Hemophilia Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hemophilia Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hemophilia Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer AG
Pfizer, Inc.
Novo Nordisk A/S
Baxter International Inc.
Biogen Idec, Inc.
Genetics Institute
Alpha Therapeutics Corporation
Expression Therapeutics
Swedish Orphan Biovitrum AB.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemophilia Therapeutics, market overview.
Chapter 2: Global Hemophilia Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Hemophilia Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemophilia Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Hemophilia Therapeutics Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Hemophilia Therapeutics Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Hemophilia Therapeutics Overall Market Size
    2.1 Global Hemophilia Therapeutics Market Size: 2022 VS 2029
    2.2 Global Hemophilia Therapeutics Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Hemophilia Therapeutics Players in Global Market
    3.2 Top Global Hemophilia Therapeutics Companies Ranked by Revenue
    3.3 Global Hemophilia Therapeutics Revenue by Companies
    3.4 Top 3 and Top 5 Hemophilia Therapeutics Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Hemophilia Therapeutics Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Hemophilia Therapeutics Players in Global Market
        3.6.1 List of Global Tier 1 Hemophilia Therapeutics Companies
        3.6.2 List of Global Tier 2 and Tier 3 Hemophilia Therapeutics Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Hemophilia Therapeutics Market Size Markets, 2022 & 2029
        4.1.2 Hemophilia A
        4.1.3 Hemophilia B
        4.1.4 Hemophilia C
    4.2 By Type - Global Hemophilia Therapeutics Revenue & Forecasts
        4.2.1 By Type - Global Hemophilia Therapeutics Revenue, 2018-2023
        4.2.2 By Type - Global Hemophilia Therapeutics Revenue, 2024-2029
        4.2.3 By Type - Global Hemophilia Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Hemophilia Therapeutics Market Size, 2022 & 2029
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Ambulatory Surgical Centers
    5.2 By Application - Global Hemophilia Therapeutics Revenue & Forecasts
        5.2.1 By Application - Global Hemophilia Therapeutics Revenue, 2018-2023
        5.2.2 By Application - Global Hemophilia Therapeutics Revenue, 2024-2029
        5.2.3 By Application - Global Hemophilia Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Hemophilia Therapeutics Market Size, 2022 & 2029
    6.2 By Region - Global Hemophilia Therapeutics Revenue & Forecasts
        6.2.1 By Region - Global Hemophilia Therapeutics Revenue, 2018-2023
        6.2.2 By Region - Global Hemophilia Therapeutics Revenue, 2024-2029
        6.2.3 By Region - Global Hemophilia Therapeutics Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Hemophilia Therapeutics Revenue, 2018-2029
        6.3.2 US Hemophilia Therapeutics Market Size, 2018-2029
        6.3.3 Canada Hemophilia Therapeutics Market Size, 2018-2029
        6.3.4 Mexico Hemophilia Therapeutics Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Hemophilia Therapeutics Revenue, 2018-2029
        6.4.2 Germany Hemophilia Therapeutics Market Size, 2018-2029
        6.4.3 France Hemophilia Therapeutics Market Size, 2018-2029
        6.4.4 U.K. Hemophilia Therapeutics Market Size, 2018-2029
        6.4.5 Italy Hemophilia Therapeutics Market Size, 2018-2029
        6.4.6 Russia Hemophilia Therapeutics Market Size, 2018-2029
        6.4.7 Nordic Countries Hemophilia Therapeutics Market Size, 2018-2029
        6.4.8 Benelux Hemophilia Therapeutics Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Hemophilia Therapeutics Revenue, 2018-2029
        6.5.2 China Hemophilia Therapeutics Market Size, 2018-2029
        6.5.3 Japan Hemophilia Therapeutics Market Size, 2018-2029
        6.5.4 South Korea Hemophilia Therapeutics Market Size, 2018-2029
        6.5.5 Southeast Asia Hemophilia Therapeutics Market Size, 2018-2029
        6.5.6 India Hemophilia Therapeutics Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Hemophilia Therapeutics Revenue, 2018-2029
        6.6.2 Brazil Hemophilia Therapeutics Market Size, 2018-2029
        6.6.3 Argentina Hemophilia Therapeutics Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Hemophilia Therapeutics Revenue, 2018-2029
        6.7.2 Turkey Hemophilia Therapeutics Market Size, 2018-2029
        6.7.3 Israel Hemophilia Therapeutics Market Size, 2018-2029
        6.7.4 Saudi Arabia Hemophilia Therapeutics Market Size, 2018-2029
        6.7.5 UAE Hemophilia Therapeutics Market Size, 2018-2029
7 Hemophilia Therapeutics Companies Profiles
    7.1 Bayer AG
        7.1.1 Bayer AG Company Summary
        7.1.2 Bayer AG Business Overview
        7.1.3 Bayer AG Hemophilia Therapeutics Major Product Offerings
        7.1.4 Bayer AG Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.1.5 Bayer AG Key News & Latest Developments
    7.2 Pfizer, Inc.
        7.2.1 Pfizer, Inc. Company Summary
        7.2.2 Pfizer, Inc. Business Overview
        7.2.3 Pfizer, Inc. Hemophilia Therapeutics Major Product Offerings
        7.2.4 Pfizer, Inc. Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.2.5 Pfizer, Inc. Key News & Latest Developments
    7.3 Novo Nordisk A/S
        7.3.1 Novo Nordisk A/S Company Summary
        7.3.2 Novo Nordisk A/S Business Overview
        7.3.3 Novo Nordisk A/S Hemophilia Therapeutics Major Product Offerings
        7.3.4 Novo Nordisk A/S Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.3.5 Novo Nordisk A/S Key News & Latest Developments
    7.4 Baxter International Inc.
        7.4.1 Baxter International Inc. Company Summary
        7.4.2 Baxter International Inc. Business Overview
        7.4.3 Baxter International Inc. Hemophilia Therapeutics Major Product Offerings
        7.4.4 Baxter International Inc. Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.4.5 Baxter International Inc. Key News & Latest Developments
    7.5 Biogen Idec, Inc.
        7.5.1 Biogen Idec, Inc. Company Summary
        7.5.2 Biogen Idec, Inc. Business Overview
        7.5.3 Biogen Idec, Inc. Hemophilia Therapeutics Major Product Offerings
        7.5.4 Biogen Idec, Inc. Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.5.5 Biogen Idec, Inc. Key News & Latest Developments
    7.6 Genetics Institute
        7.6.1 Genetics Institute Company Summary
        7.6.2 Genetics Institute Business Overview
        7.6.3 Genetics Institute Hemophilia Therapeutics Major Product Offerings
        7.6.4 Genetics Institute Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.6.5 Genetics Institute Key News & Latest Developments
    7.7 Alpha Therapeutics Corporation
        7.7.1 Alpha Therapeutics Corporation Company Summary
        7.7.2 Alpha Therapeutics Corporation Business Overview
        7.7.3 Alpha Therapeutics Corporation Hemophilia Therapeutics Major Product Offerings
        7.7.4 Alpha Therapeutics Corporation Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.7.5 Alpha Therapeutics Corporation Key News & Latest Developments
    7.8 Expression Therapeutics
        7.8.1 Expression Therapeutics Company Summary
        7.8.2 Expression Therapeutics Business Overview
        7.8.3 Expression Therapeutics Hemophilia Therapeutics Major Product Offerings
        7.8.4 Expression Therapeutics Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.8.5 Expression Therapeutics Key News & Latest Developments
    7.9 Swedish Orphan Biovitrum AB.
        7.9.1 Swedish Orphan Biovitrum AB. Company Summary
        7.9.2 Swedish Orphan Biovitrum AB. Business Overview
        7.9.3 Swedish Orphan Biovitrum AB. Hemophilia Therapeutics Major Product Offerings
        7.9.4 Swedish Orphan Biovitrum AB. Hemophilia Therapeutics Revenue in Global Market (2018-2023)
        7.9.5 Swedish Orphan Biovitrum AB. Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Hemophilia Therapeutics Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?